Evidence map›Paper›PMID 40723918›Full record

ReviewBiomolecules2025

PHF20L1: An Epigenetic Regulator in Cancer and Beyond.

Yishan Wang, Qin Hu, Haixia Zhao, Lulu Zeng, Zhongwei Zhao, Xia Li, Qiaoyou Weng, Yang Yang, Minjiang Chen, Jiansong Ji and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yishan WangZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Qin HuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Haixia ZhaoZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Lulu ZengZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Zhongwei ZhaoZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Xia LiZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Qiaoyou WengZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Yang YangZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Minjiang ChenZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Jiansong JiZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Rongfang QiuZhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affliated Hospital of Wenzhou Medical University, Lishui 323000, China.ORCID 0000-0002-4945-2345

Funding

Science and Technology Department of Zhejiang Province No. LY22H160040
6 · The paper itself

Abstract

Plant homeodomain (PHD) finger protein 20-like 1 (PHF20L1) is a novel epigenetic "reader" that specifically recognises histone post-translational modifications (PTMs) via its Tudor and PHD finger domains, thereby regulating chromatin remodelling, DNA damage repair, and oncogene transcriptional activation. This review comprehensively summarises the role of PHF20L1 in various cancers, including breast, ovarian, and colorectal cancers, as well as retinoblastomas, and elucidates its molecular mechanisms of action in cancer pathogenesis. Accumulating evidence indicates that PHF20L1 is upregulated in these malignancies and drives tumour progression by promoting proliferation, metastasis, and immune evasion. Furthermore, PHF20L1 orchestrates tumour-related gene expression by interacting with key epigenetic complexes. Given its unique structural features, we propose novel strategies for developing small-molecule inhibitors and combinatorial therapies, providing a theoretical basis for targeted epigenetic regulation for precision treatment. Future research should further investigate the molecular regulatory networks of PHF20L1 in different cancers and other human diseases and focus on developing specific small-molecule inhibitors to enable precision-targeted therapies.

Indexed as

Epigenesis, GeneticHomeodomain ProteinsNeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansProtein Processing, Post-TranslationalHomeodomain Proteinscancerepigenetic regulationhistone methylationPHF20L1targeted therapy

Identifiers

PMID40723918
PMCPMC12292733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.